Date: Tuesday, March 5, 2024 Time: 1:00pm - 2:00pm ET TITLE: Advocating for Access to Behavioral Health Treatment for the Bleeding Disorders Community WEBINAR OBJECTIVE: This presentation will educate HTC providers about the barriers to access to inpatient and residential mental health and substance use treatment facilities for people with bleeding disorders. It will provide Read the full article...

Date: Thursday, March 14, 2024 Time: 1:00pm - 2:00pm ET TITLE: Exploring the Science and Possibilities of Gene Therapy in Hemophilia WEBINAR OVERVIEW: By attending this webinar, you will discover the scientific approach of gene therapy, understand gene therapy objectives for patients with hemophilia, and explore the shared decision-making process to accompany your patients in Read the full article...

Date: Tuesday, May 7, 2024 Time: 2:00pm - 3:00pm ET TITLE: Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment, including the latest data in infants WEBINAR OBJECTIVE: Dr. Mike Silvey will share his perspective on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal Read the full article...

Date: Tuesday, May 14, 2024 Time: 2:00pm - 3:00pm ET TITLE: Hemophilia Alliance Network Services/Emerging Therapy Solutions A Gene Therapy Payer Contract WEBINAR DESCRIPTION: The past twelve to eighteen months have been landmark times for gene therapy treatments for individuals with bleeding disorders. While the third party payers, reinsurers and prescription benefit plans have begun Read the full article...

Date: Wednesday, June 5, 2024 Time: 1:00pm - 2:00pm ET TOPIC: Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® WEBINAR OVERVIEW: This session includes key information about Jivi including, safety and efficacy data from the clinical trials, step-wise dosing and Jivi RWE Data from Read the full article...

Date: Thursday, June 20, 2024 Time: 2:00pm - 3:00pm ET Title: Practice Considerations for ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Objectives: Review coverage and typical prior authorization criteria for ROCTAVIAN Review considerations and pricing education available for single-case agreements Hemophilia Alliance’s gene therapy support for Member Hemophilia Treatment Centers Speakers: Josh Sammon, PharmD, Senior Director, Market Access, Hemophilia Read the full article...

Date: Tuesday, June 25, 2024 Time: 1:00pm - 2:00pm ET Title: Wilate Prophylaxis in VWD – Results from the WIL-31 Study Objectives: 1) Understand the bleeding symptoms experienced by folks with von Willebrand disease 2) Understand the benefits of wilate prophylaxis in von Willebrand disease across different ages and types 3) Understand the lack of Read the full article...

Date: Tuesday, July 16, 2024 Time: 2:00pm - 3:00pm ET Discussion Topic: VWD Case-Based Experience Description: Join our expert, Dr. Maissaa Janbain, MD, for an interactive discussion about managing patients who are living with VWD. Dr. Janbain will guide you through a VWD case-based experience, including reviewing treatment history and discussing how VONVENDI may be Read the full article...

Date: Thursday, March 20th, 2025 Time: 2:00pm - 3:00pm ET       TITLE: Takeda FVIII Portfolio OBJECTIVE: Please join Takeda leadership to review Takeda FVIII Products & Resources Available. INTENDED AUDIENCE: All HTC staff SPEAKER: Anthea Cherednichenko, VP US Hematology Franchise Head Anthea leads the sales and marketing teams for Takeda’s Hematology portfolio. Anthea Read the full article...

Date: Thursday, April 3rd, 2025 Time: 2:00pm - 3:00pm ET         WEBINAR TOPIC: Alhemo (concizumab-mtci): A new option for patients living with hemophilia A or B with inhibitors OBJECTIVE: To provide a prescribing information overview of the recently FDA approved medication, Alhemo (concizumab-mtci), for patients living with hemophilia A or B with Read the full article...